Breaking News
May 3, 2019 - Vaping and Smoking May Signal Greater Motivation to Quit
May 3, 2019 - Dementia looks different in brains of Hispanics
May 3, 2019 - Short-Staffed Nursing Homes See Drop In Medicare Ratings
May 3, 2019 - Study of teens with eating disorders explores how substance users differ from non-substance users
May 3, 2019 - Scientists develop new video game that may help in the study of Alzheimer’s
May 3, 2019 - Arc Bio introduces Galileo Pathogen Solution product line at ASM Clinical Virology Symposium
May 3, 2019 - Cornell University study uncovers relationship between starch digestion gene and gut bacteria
May 3, 2019 - How to Safely Use Glucose Meters and Test Strips for Diabetes
May 3, 2019 - Anti-inflammatory drugs ineffective for prevention of Alzheimer’s disease
May 3, 2019 - Study tracks Pennsylvania’s oil and gas waste-disposal practices
May 3, 2019 - Creating a better radiation diagnostic test for astronauts
May 3, 2019 - Vegans are often deficient in these four nutrients
May 3, 2019 - PPDC announces seed grants to develop medical devices for children
May 3, 2019 - Study maps out the frequency and impact of water polo head injuries
May 3, 2019 - Research on Reddit identifies risks associated with unproven treatments for opioid addiction
May 3, 2019 - Good smells may help ease tobacco cravings
May 3, 2019 - Medical financial hardship found to be very common among people in the United States
May 3, 2019 - Researchers develop multimodal system for personalized post-stroke rehabilitation
May 3, 2019 - Study shows significant mortality benefit with CABG over percutaneous coronary intervention
May 3, 2019 - Will gene-editing of human embryos ever be justifiable?
May 3, 2019 - FDA Approves Dengvaxia (dengue vaccine) for the Prevention of Dengue Disease in Endemic Regions
May 3, 2019 - Why Tonsillitis Keeps Coming Back
May 3, 2019 - Fighting the opioid epidemic with data
May 3, 2019 - Maggot sausages may soon be a reality
May 3, 2019 - Deletion of ATDC gene prevents development of pancreatic cancer in mice
May 2, 2019 - Targeted Therapy Promising for Rare Hematologic Cancer
May 2, 2019 - Alzheimer’s disease is a ‘double-prion disorder,’ study shows
May 2, 2019 - Reservoir bugs: How one bacterial menace makes its home in the human stomach
May 2, 2019 - Clinical, Admin Staff From Cardiology Get Sneak Peek at Epic
May 2, 2019 - Depression increases hospital use and mortality in children
May 2, 2019 - Vicon and NOC support CURE International to create first gait lab in Ethiopia
May 2, 2019 - Researchers use 3D printer to make paper organs
May 2, 2019 - Viral infection in utero associated with behavioral abnormalities in offspring
May 2, 2019 - U.S. Teen Opioid Deaths Soaring
May 2, 2019 - Opioid distribution data should be public
May 2, 2019 - In the Spotlight: “I’m learning every single day”
May 2, 2019 - 2019 Schaefer Scholars Announced
May 2, 2019 - Podcast: KHN’s ‘What The Health?’ Bye-Bye, ACA, And Hello ‘Medicare-For-All’?
May 2, 2019 - Study describes new viral molecular evasion mechanism used by cytomegalovirus
May 2, 2019 - SLU study suggests a more equitable way for Medicare reimbursement
May 2, 2019 - Scientists discover first gene involved in lower urinary tract obstruction
May 2, 2019 - Researchers identify 34 genes associated with increased risk of ovarian cancer
May 2, 2019 - Many low-income infants receive formula in the first few days of life, finds study
May 2, 2019 - Global study finds high success rate for hip and knee replacements
May 2, 2019 - Taking depression seriously: What is it?
May 2, 2019 - With Head Injuries Mounting, Will Cities Put Their Feet Down On E-Scooters?
May 2, 2019 - Scientists develop small fluorophores for tracking metabolites in living cells
May 2, 2019 - Study casts new light into how mothers’ and babies’ genes influence birth weight
May 2, 2019 - Researchers uncover new brain mechanisms regulating body weight
May 2, 2019 - Organ-on-chip systems offered to Asia-Pacific regions by Sydney’s AXT
May 2, 2019 - Adoption of new rules drops readmission penalties against safety net hospitals
May 2, 2019 - Kids and teens who consume zero-calorie sweetened beverages do not save calories
May 2, 2019 - Improved procedure for cancer-related erectile dysfunction
May 2, 2019 - Hormone may improve social behavior in autism
May 2, 2019 - Alzheimer’s disease may be caused by infectious proteins called prions
May 2, 2019 - Even Doctors Can’t Navigate Our ‘Broken Health Care System’
May 2, 2019 - Study looks at the impact on criminal persistence of head injuries
May 2, 2019 - Honey ‘as high in sugars as table sugar’
May 2, 2019 - Innovations to U.S. food system could help consumers in choosing healthy foods
May 2, 2019 - FDA Approves Mavyret (glecaprevir and pibrentasvir) as First Treatment for All Genotypes of Hepatitis C in Pediatric Patients
May 2, 2019 - Women underreport prevalence and intensity of their own snoring
May 2, 2019 - Concussion summit focuses on science behind brain injury
May 2, 2019 - Booker’s Argument For Environmental Justice Stays Within The Lines
May 2, 2019 - Cornell research explains increased metastatic cancer risk in diabetics
May 2, 2019 - Mount Sinai study provides fresh insights into cellular pathways that cause cancer
May 2, 2019 - Researchers to study link between prenatal pesticide exposures and childhood ADHD
May 2, 2019 - CoGEN Congress 2019: Speakers’ overviews
May 2, 2019 - A new strategy for managing diabetic macular edema in people with good vision
May 2, 2019 - Sagent Pharmaceuticals Issues Voluntary Nationwide Recall of Ketorolac Tromethamine Injection, USP, 60mg/2mL (30mg per mL) Due to Lack of Sterility Assurance
May 2, 2019 - Screen time associated with behavioral problems in preschoolers
May 2, 2019 - Hormone reduces social impairment in kids with autism | News Center
May 2, 2019 - Researchers synthesize peroxidase-mimicking nanozyme with low cost and superior catalytic activity
May 2, 2019 - Study results of a potential drug to treat Type 2 diabetes in children announced
May 2, 2019 - Multigene test helps doctors to make effective treatment decisions for breast cancer patients
May 2, 2019 - UNC School of Medicine initiative providing unique care to dementia patients
May 2, 2019 - Nestlé Health Science and VHP join forces to launch innovative COPES program for cancer patients
May 2, 2019 - Study examines how our brain generates consciousness and loses it during anesthesia
May 2, 2019 - Transition Support Program May Aid Young Adults With Type 1 Diabetes
May 2, 2019 - Study shows how neutrophils exacerbate atherosclerosis by inducing smooth muscle-cell death
May 2, 2019 - Research reveals complexity of how we make decisions
Big data study identifies drugs that increase risk of psychosis in youth with ADHD

Big data study identifies drugs that increase risk of psychosis in youth with ADHD

Big data study identifies drugs that increase risk of psychosis in youth with ADHD
Researchers evaluated the two most common ADHD treatments and found that certain drugs increase risk of psychosis. Credit: McLean Hospital

Certain drugs prescribed to teens and young adults with ADHD increase their risk of psychosis, say researchers at McLean Hospital and Harvard Medical School. Approximately 5 million individuals in the U.S. under the age of 25 are prescribed these drugs for the treatment of ADHD.

The researchers evaluated the two most common ADHD treatments and found that, although the risk of psychosis is low, it is greater for patients who are taking amphetamines (marketed as Adderall and Vyvanse) than for those taking methylphenidates (marketed as Ritalin or Concerta).

“The findings are concerning because the use of amphetamines in adolescents and young adults has more than tripled in recent years. More and more patients are being treated with these medications,” said researcher Lauren V. Moran, MD, lead author of the paper publishing the results in the New England Journal of Medicine on March 21, 2019.

“There is not a lot of research comparing the safety profiles of amphetamines and methylphenidate, despite increasing use of these medications,” said Moran, although clinicians have long observed “patients without previous psychiatric history coming with psychosis in the setting of stimulant use.”

The study examined information from two large commercial insurance claims databases on patients ages 13 to 25 years old with ADHD who started taking amphetamines or methylphenidate between January 1, 2004, and September 30, 2015. In looking at these 221,846 individuals, the researchers found that one out of every 486 patients started on an amphetamine developed psychosis that required treatment with antipsychotic medication compared to 1 in 1,046 patients started on a methylphenidate.

Despite the increased risk, Moran emphasizes that the study was limited to youth who had been recently diagnosed with ADHD and therefore only recently begun treatment. “People who have been on a drug like Adderall for a long time who are taking the drug as prescribed and are tolerating it well are not likely to experience this problem” said Moran.

Funded by the National Institutes of Health, under award number K23MH110564, the study analyzed data from commercial insurance claims on the Aetion Evidence PlatformTM. The Aetion platform uses real-world data to quickly generate regulatory-grade evidence. It is also being used by the FDA in its ongoing real-world evidence demonstration program.

This study represents the first time this kind of analysis has been done with data from routine patient care rather than with clinical trial data. Using this type of data ensures that study results reflect treatment patterns in large and varied populations, in contrast to the precisely uniform care received by subjects in controlled research trials. The results, therefore, are more likely to be relevant to a wide group of patients.

“We analyzed two large insurance claims databases to understand the risk for patients who start taking amphetamines to treat ADHD in a way that aligns with real-world evidence generation processes suggested by regulatory agencies,” said Sebastian Schneeweiss, MD, ScD, professor at Harvard Medical School, report author, and Aetion co-founder. “The study illustrates the importance of using data from the real world, from diverse patients, to better understand the safety of commonly prescribed medications and allow physicians to weigh benefits and risks.”


Study explores use of ADHD medications during pregnancy and risk of birth defects


More information:
“Psychosis with Amphetamine or Methylphenidate in Attention Deficit Disorder,” New England Journal of Medicine (2019).


Provided by
McLean Hospital

Citation:
Big data study identifies drugs that increase risk of psychosis in youth with ADHD (2019, March 20)
retrieved 20 March 2019
from https://medicalxpress.com/news/2019-03-big-drugs-psychosis-youth-adhd.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.

Tagged with:

About author

Related Articles